The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator

European Journal of Surgical Oncology

Volumn 41, Issue 7, 2015, Pages 859-867

  Ayez, N ^a   Van Der Stok, E P ^a   Grunhagen D J ^a   Rothbarth, J ^a   Van Meerten, E ^a   Eggermont, A M ^b   Verhoef, C ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Clinical risk score; Liver metastases; Surgery

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; FOLINIC ACID; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL RISK SCORE; COLORECTAL LIVER METASTASIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; ABDOMINAL SURGERY; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LYMPH NODE METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, MULTIPLE PRIMARY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROPENSITY SCORE; RISK ASSESSMENT; RISK FACTOR; SECONDARY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; ORGANOPLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84930765812     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2015.04.012     Document Type: Article

References (36)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2 2011 69 90
2. A. de Gramont, A. Figer, M. Seymour, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2000 2938 2947
3. J.Y. Douillard, D. Cunningham, A.D. Roth, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 9209 2000 1041 1047
4. L.B. Saltz, J.V. Cox, C. Blanke, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 13 2000 905 914
5. M. Rees, P.P. Tekkis, F.K. Welsh, T. O'Rourke, and T.G. John Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients Ann Surg 247 1 2008 125 135
6. A.E. van der Pool, J.H. de Wilt, Z.S. Lalmahomed, A.M. Eggermont, J.N. Ijzermans, and C. Verhoef Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases Br J Surg 97 3 2010 383 390
7. N.J. Petrelli Perioperative or adjuvant therapy for resectable colorectal hepatic metastases J Clin Oncol 26 30 2008 4862 4863
8. E. Mitry, A.L. Fields, H. Bleiberg, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials J Clin Oncol 26 30 2008 4906 4911
9. G. Portier, D. Elias, O. Bouche, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial J Clin Oncol 24 31 2006 4976 4982
10. B. Nordlinger, H. Sorbye, B. Glimelius, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Lancet 371 9617 2008 1007 1016
11. B. Nordlinger, H. Sorbye, B. Glimelius, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial Lancet Oncol 14 12 2013 1208 1215
12. S. Benoist, and B. Nordlinger The role of preoperative chemotherapy in patients with resectable colorectal liver metastases Ann Surg Oncol 16 9 2009 2385 2390
13. M. Minagawa, J. Yamamoto, T. Kosuge, Y. Matsuyama, S. Miyagawa, and M. Makuuchi Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation Arch Surg 142 3 2007 269 276 discussion 277
14. B. Nordlinger, M. Guiguet, J.C. Vaillant, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie Cancer 77 7 1996 1254 1262
15. Y. Fong, J. Fortner, R.L. Sun, M.F. Brennan, and L.H. Blumgart Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases Ann Surg 230 3 1999 309 318 discussion 318-21
16. S. Iwatsuki, I. Dvorchik, J.R. Madariaga, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system J Am Coll Surg 189 3 1999 291 299
17. I. Nagashima, T. Takada, K. Matsuda, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection J Hepatobiliary Pancreat Surg 11 2 2004 79 83
18. R. Konopke, S. Kersting, M. Distler, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases Liver Int 29 1 2009 89 102
19. T. Mala, G. Bohler, O. Mathisen, A. Bergan, and O. Soreide Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg 26 11 2002 1348 1353
20. C. Reissfelder, N.N. Rahbari, M. Koch, et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases Ann Surg Oncol 16 12 2009 3279 3288
21. E.A. Eisenhauer, P. Therasse, J. Bogaerts, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247
22. C. Tournigand, T. Andre, E. Achille, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 2004 229 237
23. M.T. Seymour, T.S. Maughan, J.A. Ledermann, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 9582 2007 143 152
24. M. Koopman, N.F. Antonini, J. Douma, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial Lancet 370 9582 2007 135 142
25. H. Hurwitz, L. Fehrenbacher, W. Novotny, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
26. L.B. Saltz, S. Clarke, E. Diaz-Rubio, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 12 2008 2013 2019
27. E. Van Cutsem, C.H. Kohne, E. Hitre, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
28. J.Y. Douillard, S. Siena, J. Cassidy, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 31 2010 4697 4705
29. J.Y. Douillard, S. Siena, J. Cassidy, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer Ann Oncol 25 7 2014 1346 1355
30. M.J. O'Connell, M.A. Adson, A.J. Schutt, J. Rubin, C.G. Moertel, and D.M. Ilstrup Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver Mayo Clin Proc 60 8 1985 517 520
31. J.S. Tomlinson, W.R. Jarnagin, R.P. DeMatteo, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure J Clin Oncol 25 29 2007 4575 4580
32. R. Parks, M. Gonen, N. Kemeny, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents J Am Coll Surg 204 5 2007 753 761 discussion 761-3
33. N.N. Rahbari, C. Reissfelder, H. Schulze-Bergkamen, et al. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy BMC Cancer 14 2014 174
34. R. Adam, P. Bhangui, G. Poston, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 252 5 2010 774 787
35. H. Sorbye, M. Mauer, T. Gruenberger, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983) Ann Surg 255 3 2012 534 539
36. W.R. Jarnagin, and M. D'Angelica Systemic therapy for patients with resectable hepatic colorectal metastases: improving patient selection Ann Surg Oncol 21 1 2014 11 12